Literature DB >> 34793693

Rescue of α-synuclein aggregation in Parkinson's patient neurons by synergistic enhancement of ER proteostasis and protein trafficking.

Iva Stojkovska1, Willayat Y Wani1, Friederike Zunke2, Nandkishore R Belur1, Egor A Pavlenko1, Nkatha Mwenda1, Karan Sharma1, Laetitia Francelle1, Joseph R Mazzulli3.   

Abstract

Neurodegenerative disorders are characterized by a collapse in proteostasis, as shown by the accumulation of insoluble protein aggregates in the brain. Proteostasis involves a balance of protein synthesis, folding, trafficking, and degradation, but how aggregates perturb these pathways is unknown. Using Parkinson's disease (PD) patient midbrain cultures, we find that aggregated α-synuclein induces endoplasmic reticulum (ER) fragmentation and compromises ER protein folding capacity, leading to misfolding and aggregation of immature lysosomal β-glucocerebrosidase. Despite this, PD neurons fail to initiate the unfolded protein response, indicating perturbations in sensing or transducing protein misfolding signals in the ER. Small molecule enhancement of ER proteostasis machinery promotes β-glucocerebrosidase solubility, while simultaneous enhancement of trafficking improves ER morphology, lysosomal function, and reduces α-synuclein. Our studies suggest that aggregated α-synuclein perturbs the ability of neurons to respond to misfolded proteins in the ER, and that synergistic enhancement of multiple proteostasis branches may provide therapeutic benefit in PD.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ER stress; Parkinson's disease; alpha-synuclein; beta-glucocerebrosidase; iPSC-derived midbrain dopaminergic neurons; lysosomal dysfunction; protein aggregation

Mesh:

Substances:

Year:  2021        PMID: 34793693      PMCID: PMC8815333          DOI: 10.1016/j.neuron.2021.10.032

Source DB:  PubMed          Journal:  Neuron        ISSN: 0896-6273            Impact factor:   18.688


  76 in total

1.  Dantrolene inhibition of sarcoplasmic reticulum Ca2+ release by direct and specific action at skeletal muscle ryanodine receptors.

Authors:  B R Fruen; J R Mickelson; C F Louis
Journal:  J Biol Chem       Date:  1997-10-24       Impact factor: 5.157

2.  Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.

Authors:  Joseph R Mazzulli; You-Hai Xu; Ying Sun; Adam L Knight; Pamela J McLean; Guy A Caldwell; Ellen Sidransky; Gregory A Grabowski; Dimitri Krainc
Journal:  Cell       Date:  2011-06-23       Impact factor: 41.582

3.  Perturbation of cellular calcium induces secretion of luminal ER proteins.

Authors:  C Booth; G L Koch
Journal:  Cell       Date:  1989-11-17       Impact factor: 41.582

4.  Reversible Conformational Conversion of α-Synuclein into Toxic Assemblies by Glucosylceramide.

Authors:  Friederike Zunke; Alexandra C Moise; Nandkishore R Belur; Eilrayna Gelyana; Iva Stojkovska; Haris Dzaferbegovic; Nicholas J Toker; Sohee Jeon; Kristina Fredriksen; Joseph R Mazzulli
Journal:  Neuron       Date:  2017-12-28       Impact factor: 17.173

5.  Synthesis of beta-hexosaminidase in cell-free translation and in intact fibroblasts: an insoluble precursor alpha chain in a rare form of Tay-Sachs disease.

Authors:  R L Proia; E F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

6.  LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase.

Authors:  David Reczek; Michael Schwake; Jenny Schröder; Heather Hughes; Judith Blanz; Xiaoying Jin; William Brondyk; Scott Van Patten; Tim Edmunds; Paul Saftig
Journal:  Cell       Date:  2007-11-16       Impact factor: 41.582

7.  Sequential interaction of the chaperones BiP and GRP94 with immunoglobulin chains in the endoplasmic reticulum.

Authors:  J Melnick; J L Dul; Y Argon
Journal:  Nature       Date:  1994-08-04       Impact factor: 49.962

8.  Toxic properties of microsome-associated alpha-synuclein species in mouse primary neurons.

Authors:  Emanuela Colla; Giulia Panattoni; Alessio Ricci; Caterina Rizzi; Lucia Rota; Nicola Carucci; Verdiana Valvano; Francesco Gobbo; Simona Capsoni; Michael K Lee; Antonino Cattaneo
Journal:  Neurobiol Dis       Date:  2017-12-12       Impact factor: 5.996

9.  Membrane expansion alleviates endoplasmic reticulum stress independently of the unfolded protein response.

Authors:  Sebastian Schuck; William A Prinz; Kurt S Thorn; Christiane Voss; Peter Walter
Journal:  J Cell Biol       Date:  2009-11-09       Impact factor: 10.539

10.  Pharmacologic IRE1/XBP1s activation confers targeted ER proteostasis reprogramming.

Authors:  Julia M D Grandjean; Aparajita Madhavan; Lauren Cech; Bryan O Seguinot; Ryan J Paxman; Emery Smith; Louis Scampavia; Evan T Powers; Christina B Cooley; Lars Plate; Timothy P Spicer; Jeffery W Kelly; R Luke Wiseman
Journal:  Nat Chem Biol       Date:  2020-07-20       Impact factor: 15.040

View more
  11 in total

Review 1.  Macroautophagy in CNS health and disease.

Authors:  Christopher J Griffey; Ai Yamamoto
Journal:  Nat Rev Neurosci       Date:  2022-05-03       Impact factor: 38.755

Review 2.  Induced pluripotent stem cells: a tool for modeling Parkinson's disease.

Authors:  Anindita Bose; Gregory A Petsko; Lorenz Studer
Journal:  Trends Neurosci       Date:  2022-06-03       Impact factor: 16.978

3.  LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson's disease.

Authors:  Maria Kedariti; Emanuele Frattini; Pascale Baden; Susanna Cogo; Laura Civiero; Elena Ziviani; Gianluca Zilio; Federico Bertoli; Massimo Aureli; Alice Kaganovich; Mark R Cookson; Leonidas Stefanis; Matthew Surface; Michela Deleidi; Alessio Di Fonzo; Roy N Alcalay; Hardy Rideout; Elisa Greggio; Nicoletta Plotegher
Journal:  NPJ Parkinsons Dis       Date:  2022-07-19

Review 4.  Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies.

Authors:  Sindhu Menon; Sabrina Armstrong; Amir Hamzeh; Naomi P Visanji; Sergio Pablo Sardi; Anurag Tandon
Journal:  Front Neurol       Date:  2022-05-09       Impact factor: 4.086

Review 5.  GBA Variants and Parkinson Disease: Mechanisms and Treatments.

Authors:  Laura Smith; Anthony H V Schapira
Journal:  Cells       Date:  2022-04-08       Impact factor: 7.666

6.  Recombinant pro-CTSD (cathepsin D) enhances SNCA/α-Synuclein degradation in α-Synucleinopathy models.

Authors:  Susy Prieto Huarcaya; Alice Drobny; André R A Marques; Alessandro Di Spiezio; Jan Philipp Dobert; Denise Balta; Christian Werner; Tania Rizo; Lisa Gallwitz; Simon Bub; Iva Stojkovska; Nandkishore R Belur; Jens Fogh; Joseph R Mazzulli; Wei Xiang; Amitkumar Fulzele; Mario Dejung; Markus Sauer; Beate Winner; Stefan Rose-John; Philipp Arnold; Paul Saftig; Friederike Zunke
Journal:  Autophagy       Date:  2022-04-28       Impact factor: 13.391

Review 7.  Contribution of Autophagy-Lysosomal Pathway in the Exosomal Secretion of Alpha-Synuclein and Its Impact in the Progression of Parkinson's Disease.

Authors:  Denisse Sepúlveda; Marisol Cisternas-Olmedo; Javiera Arcos; Melissa Nassif; René L Vidal
Journal:  Front Mol Neurosci       Date:  2022-02-17       Impact factor: 5.639

8.  Interaction of Alpha Synuclein and Microtubule Organization Is Linked to Impaired Neuritic Integrity in Parkinson's Patient-Derived Neuronal Cells.

Authors:  Lukas Seebauer; Yanni Schneider; Alice Drobny; Sonja Plötz; Tomas Koudelka; Andreas Tholey; Iryna Prots; Beate Winner; Friederike Zunke; Jürgen Winkler; Wei Xiang
Journal:  Int J Mol Sci       Date:  2022-02-05       Impact factor: 5.923

Review 9.  Clinical Sphingolipids Pathway in Parkinson's Disease: From GCase to Integrated-Biomarker Discovery.

Authors:  Ali Esfandiary; David Isaac Finkelstein; Nicolas Hans Voelcker; David Rudd
Journal:  Cells       Date:  2022-04-15       Impact factor: 7.666

Review 10.  Aging conundrum: A perspective for ovarian aging.

Authors:  Jiachen Wu; Yang Liu; Yinhua Song; Lingjuan Wang; Jihui Ai; Kezhen Li
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-19       Impact factor: 6.055

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.